Royalty Pharma RPRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $630.58M+11.0% | $621.99M+4.8% | $609.29M+7.9% | $578.67M+7.7% | $568.25M0.0% | ||
| $39.79M-21.2% | $50.5M+10,000% | $50.5M+10,000% | $300.5M+60,000% | $50.5M+10,000% | ||
| $159.49M+44.1% | $164.27M+143% | $118.73M+109% | $179.77M+229% | $110.71M+92.0% | ||
| $69.44M— | —— | —— | —— | $0— | ||
| $67.54M+98.3% | $233.61M+0.6% | $182.14M+207% | $368.87M+37.8% | $34.07M-94.7% | ||
| $563.04M+5.4% | $388.38M+7.4% | $427.16M-41.9% | $209.8M-22.2% | $534.18M+824% | ||
| 89.3%-4.7pp | 62.4%+1.5pp | 70.1%-60.1pp | 36.3%-13.9pp | 94%+107pp | ||
| $93.72M+43.6% | $94.17M+43.2% | $79.56M+19.6% | $68.67M+40.1% | $65.26M+47.5% | ||
| $6.23M-44.8% | $7.07M-21.8% | $6.9M-60.6% | $8.33M-37.8% | $11.29M+52.2% | ||
| -$94.78M+5.0% | -$32.47M— | $17.06M-76.1% | -$119.16M-58.4% | -$99.75M-244% | ||
| $21.76M+238% | $4.01M-87.3% | $15.95M+53.2% | $2.69M+58.1% | $6.44M+146% | ||
| $468.26M+7.8% | $355.91M+6.4% | $444.21M-44.9% | $90.64M-53.4% | $434.43M+10,267% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $294.69M+23.1% | $214.21M+2.9% | $288.22M-47.0% | $30.18M-70.4% | $239.35M+4,909% | ||
| 46.7%+4.6pp | 34.4%-0.6pp | 47.3%-49.0pp | 5.2%-13.8pp | 42.1%+41.3pp | ||
| $0.67+21.8% | $0.50+6.4% | $0.67-44.6% | $0.07-69.6% | $0.55+5,400% | ||
| $0.67+21.8% | $0.50+6.4% | $0.67-45.1% | $0.07-69.6% | $0.55+5,400% | ||
| 556.8M-3.7% | 564.5M-5.0% | 559.6M-5.6% | 562.3M-5.8% | 578.1M-3.2% | ||
| 436.8M+0.3% | 429.8M-4.1% | 431.9M-3.5% | 423.5M-6.1% | 435.5M-2.9% | ||
| -$3.7M— | $0— | $766K— | $92.54M— | $0— | ||
| -$20.17M+56.0% | —— | $18.86M-62.9% | -$30.55M+35.2% | -$45.88M-159% | ||
| -$6.68M-104% | $24.08M-52.8% | $52.48M-9.0% | -$27.42M-13,610% | -$3.28M-107% | ||
| $3.72M-72.2% | —— | —— | —— | $13.4M0.0% | ||
| $6.23M-44.8% | $7.07M-21.8% | $6.9M-60.6% | $8.33M-37.8% | $11.29M+52.2% | ||
| $173.53M+25.0% | $6.68M+730% | $129.99M+64.6% | $796K-0.1% | $138.82M+75.8% | ||
| -$272.67M+71.0% | -$299.6M— | —— | -$507.81M-144% | -$941.3M-344% | ||
| -$477.87M-195% | -$847.8M-67.7% | -$958.31M+19.7% | -$311.98M+65.1% | $503.92M+682% | ||
| $718.23M+20.5% | $827.15M+11.4% | $702.62M-0.1% | $363.98M-44.7% | $596.08M-10.3% | ||
| -$2.2M+28.1% | -$8.17M-273% | -$1.58M+4.8% | -$1.54M-126% | -$3.06M+16.9% | ||
| $50.1M-92.9% | $80.54M+53.1% | $146.49M+51.0% | $291.57M+264% | $708.78M— | ||
| $452.37M+42,697% | $733.69M+47.8% | $961.87M-19.5% | $1.11M-99.8% | $1.06M-98.8% | ||
| $42.31M+16.7% | $4.99M+53.9% | $905K-92.1% | $62.99M+1,497% | $36.26M+630% | ||
| $4.32M-65.7% | $2.88M-77.1% | $2.88M0.0% | $2.88M0.0% | $12.59M+774% | ||
| -$197.49M-55.3% | $0-100% | $12.14M+105% | -$203.94M-196% | -$127.14M-122% | ||
| $563.04M+5.4% | $388.38M+7.4% | $427.16M-41.9% | $209.8M-22.2% | $534.18M+824% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Royalty Pharma's revenue?
- Royalty Pharma (RPRX) generated $2.4B in revenue over the trailing twelve months, up 7.8% year over year.
- Is Royalty Pharma profitable?
- Royalty Pharma reported $827.3M in net income over the trailing twelve months, a 33.9% net margin.
- What is Royalty Pharma's earnings per share?
- Royalty Pharma's diluted EPS over the trailing twelve months is $1.91.
- Where does Royalty Pharma's income statement data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
